Opioid safety and naloxone
Opioid overdose is a leading cause of preventable death — over 80,000 people die annually in the US alone, according to CDC overdose surveillance data. Naloxone (Narcan) is an inexpensive, safe, and effective antidote — now available without a prescription. This guide covers the pharmacology, formulations, administration, and harm reduction context.
Scale of the opioid crisis
The opioid overdose epidemic in the US has evolved across three waves: prescription opioids (1990s–2000s), heroin (2010s), and illicitly manufactured fentanyl and fentanyl analogues (2013–present). Today, synthetic opioids account for >70% of overdose deaths. The CDC Drug Overdose Surveillance programme tracks trends in real time.
The HHS opioid statistics page and NIDA opioid overview provide regularly updated data on treatment utilisation, fatalities, and naloxone dispensing trends.
Opioid pharmacology essentials
Opioids act on G-protein-coupled μ (mu), κ (kappa), and δ (delta) opioid receptors. μ-receptor activation produces analgesia, euphoria, sedation, and — critically — respiratory depression via suppression of the pre-Bötzinger complex rhythm generator in the brainstem. For a detailed receptor pharmacology review, see NCBI StatPearls: Opioid Receptor Pharmacology.
Clinically relevant opioids by potency
| Drug | Route(s) | Oral morphine equivalent | Half-life | Key notes |
|---|---|---|---|---|
| Codeine | PO, IM | 0.15× (prodrug via CYP2D6) | 3 h | Ultra-rapid metabolisers: toxicity risk; avoid in paediatrics. See FDA restriction notice |
| Tramadol | PO | 0.1× (also serotonin/NE reuptake inhibition) | 6 h | Serotonin syndrome risk with SSRIs/SNRIs; seizures at high doses |
| Morphine | PO, IV, SC, epidural | 1× (reference) | 2–3 h | Active metabolite M6G accumulates in renal failure; avoid in CKD |
| Oxycodone | PO | 1.5× | 3–5 h | CYP2D6 and CYP3A4 metabolism; ER formulation designed as abuse-deterrent |
| Hydromorphone | PO, IV | 4–5× | 2–3 h | Higher mu selectivity; preferred in morphine-intolerant patients |
| Fentanyl | IV, transdermal, buccal | 50–100× (IV) | 2–4 h IV; 17–27 h patch | Highly lipophilic; rapid onset; patch: 72-h dosing, 3-day lag to steady state |
| Methadone | PO, IV | Variable (3–10×+ at high doses) | 8–59 h | Long, variable t½ = accumulation/OD risk; QTc prolongation; NMDA antagonism. Requires experienced prescriber |
| Buprenorphine | SL, transdermal, IV | 75–100× | 24–42 h | Partial agonist; ceiling effect on respiratory depression; treatment of OUD (Suboxone, Brixia) |
For equianalgesic dose conversions, the ASHP opioid shortage resources and the NCBI opioid conversion guide are recommended references.
Recognising an opioid overdose
The opioid overdose triad is a classic presentation, though not all three need be present — especially with fentanyl analogues where onset is extremely rapid. The SAMHSA overdose recognition toolkit provides patient-facing resources.
Miosis (<2 mm) even in low light. Exception: mixed overdose (e.g. opioid + stimulant) may cause dilated pupils.
Unresponsive to voice or sternal rub. May be associated with gurgling/snoring ("death rattle") from airway obstruction.
Breathing <8–10/min, irregular, or stopped. Cyanotic lips/fingertips. This is the proximate cause of death.
Naloxone formulations and dosing
Following the 2023 FDA approval of OTC naloxone nasal spray (Narcan 4 mg), access has expanded significantly. The DEA standing order also permits dispensing without an individual prescription in many states.
Intranasal (Narcan 4 mg, RiVive 3 mg)
Prefilled syringe with nasal atomiser. Administer one spray in one nostril; repeat in other nostril after 2–3 min if no response. No needles, no training required. Onset 5–8 min. Community-level standard of care for bystander use. Storage: room temp, avoid freezing.
Intramuscular / auto-injector (Evzio 2 mg)
Auto-injector with voice instructions. Inject into outer thigh (through clothing). Onset 3–5 min. Can be used by lay responders. The FDA Evzio Q&A covers dispensing and storage.
Intravenous / IM vial (0.4 mg/mL)
For clinical settings. IV dosing: 0.04–0.4 mg titrated to adequate ventilation (not full reversal to avoid acute withdrawal in dependent patients). Can be given as infusion (⅔ of effective bolus per hour) for long-acting opioids such as methadone. Reference: AHFS Drug Information — Naloxone.
Emergency response — step by step
Based on the SAMHSA overdose response protocol and CDC naloxone guidance:
- 1Call 911 immediately — even if you have naloxone. Many US states have Good Samaritan laws protecting bystanders who call for help from drug possession charges.
- 2Try to stimulate the person — call their name, rub your knuckles firmly on the sternum. If unresponsive, proceed.
- 3Administer naloxone — nasal spray into one nostril, or IM injection into the outer thigh. Lay the person on their back with head tilted back to open the airway.
- 4Rescue breathing — give one breath every 5 seconds. Keep the airway clear.
- 5Wait 2–3 minutes — if no improvement, administer a second dose of naloxone. Repeat as needed (fentanyl overdoses may require 3+ doses).
- 6Recovery position — once breathing is restored, place the person on their side to prevent aspiration if they vomit. Stay with them until emergency services arrive.
Harm reduction and treatment pathways
Naloxone reversal is not treatment — it is a bridge. The SAMHSA medications for opioid use disorder (MOUD) framework endorses three FDA-approved pharmacotherapies.
Methadone
Full μ-agonist; daily supervised dosing through federally-licensed OTPs. Reduces illicit opioid use, overdose death, and criminal activity. Requires careful QTc monitoring. Highly effective for high-severity OUD.
Buprenorphine (Suboxone, Sublocade)
Partial agonist; ceiling on respiratory depression. Prescribable by any DEA-licensed provider since 2023 waiver removal. Monthly injectable (Sublocade) eliminates daily dosing. First-line per ASAM guidelines.
Naltrexone (Vivitrol)
Full opioid antagonist; monthly IM injection. No abuse potential; no opioid effect. Requires full opioid detoxification first (7–10 days). Adherence is key — missed dose eliminates blockade. Good option for patients who prefer a non-opioid approach post-detox.
Community harm reduction resources
Safe opioid prescribing principles
The CDC Clinical Practice Guideline for Prescribing Opioids (2022) replaced the 2016 guideline with 12 updated recommendations. Key principles include:
Initiate at the lowest effective dose. For opioid-naive patients, avoid starting above 50 MME/day; review carefully above 90 MME/day.
Offer naloxone to all patients on long-term opioid therapy, especially those on high doses, with respiratory disease, or using benzodiazepines. 49 states allow pharmacist prescribing under standing orders.
Check the Prescription Drug Monitoring Programme (PDMP) database at each prescribing encounter to identify concurrent opioid and benzodiazepine prescriptions — the most common combination in overdose deaths.
Evaluate benefits and harms at each visit. Use validated tools (ORT, PEG, DIRE) to assess risk and function. Taper or discontinue if risks outweigh benefits — tapering should be patient-guided, not abrupt.
The DEA practitioner's manual and ASAM opioid risk evaluation guidelines provide additional regulatory and clinical context.
Frequently asked questions
What is naloxone and how does it work?
Naloxone (Narcan) is a competitive opioid receptor antagonist with high affinity for μ-opioid receptors. It rapidly displaces opioid agonists and reverses CNS and respiratory depression within 2–5 minutes of IV administration or 5–8 minutes intranasally. Its duration of action (30–90 minutes) is shorter than most opioids, so redosing and continued monitoring are essential.
Do I need a prescription to get naloxone?
In the United States, naloxone nasal spray (Narcan, RiVive) is available over the counter at most pharmacies without a prescription following a 2023 FDA standing order. Many states also have community distribution programmes providing free naloxone kits. The NEXT Distro programme and local harm reduction organisations offer naloxone at no cost.
Can naloxone be used in opioid-dependent patients?
Yes, but it will precipitate acute opioid withdrawal in dependent patients — manifesting as agitation, tachycardia, diaphoresis, vomiting, and acute pain. This is not dangerous in most circumstances but can be distressing. Use the lowest effective dose to restore adequate breathing rather than full arousal, especially in dependent patients. Naloxone does not reverse withdrawal symptoms once precipitated.
What is the difference between naloxone, naltrexone, and nalmefene?
All three are opioid receptor antagonists. Naloxone (short-acting, injectable/intranasal) is for acute overdose reversal. Naltrexone (oral or extended-release injectable, Vivitrol) is for maintenance treatment of opioid and alcohol use disorders — it is not appropriate for acute overdose. Nalmefene has a longer half-life than naloxone and is used in some countries for overdose management and is also approved for alcohol use disorder (Selincro) in Europe.
How do I store naloxone?
Store naloxone at room temperature, away from light and moisture. Avoid extreme heat (e.g. glove compartments in summer). Check the expiration date regularly. Expired naloxone may still be partially effective in an emergency — use it if nothing else is available.
What are the signs of opioid overdose?
Classic signs include: unresponsiveness or extreme sedation, slow or stopped breathing (<8 breaths/min), gurgling or choking sounds ("death rattle"), blue or grey lips/fingertips (cyanosis), pinpoint pupils (miosis), and limp body. If you observe these, call 911 immediately, administer naloxone, and perform rescue breathing if trained.